Comparative analysis of proteome in HeLa and HepG2 cell cultures before and after treatment with phenazines

The effect of phenazine compounds on prokaryotic organisms has been well studied. However, there is a large gap with regard to eukaryotic cells.

The aim of this study is the proteomic analysis of HeLa and HepG2 cell cultures before and after treatment with purified complexes of phenazine compounds from the bacterium Pseudomonas chlororaphis subsp. aurantiaca and the identification of targets for phenazines in eukaryotic cells.

In the course of this study, most proteins found in the proteome of HeLa and HepG2 cell cultures were found to be involved in the regulation of cell membrane potential, signalling cascades involved in oncogenesis, calcium regulation in cardiac muscle, nervous system function and response to xenobiotics. In addition, an accumulation of histone proteins and chromatin modifiers that promote conversion to heterochromatin was detected in HeLa and HepG2 cultures after phenazine treatment. At the same time, the content of chromatin decompaction enzymes decreases in both cultures. The concentration of some ribosomal proteins changes significantly in the HeLa cell culture, while in the HepG2 cell culture there is a massive increase in their content.

1. Chen F., Chandrashekar D. S., Varambally S., Creighton C. J. A Pan-cancer molecular subtypes revealed by massspectro metry-based proteomic characterization of more than 500 human cancers. Nature Communications, 2019, vol. 10, art. 5679. https://doi.org/10.1038/s41467-019-13528-0

2. Enroth S., Berggrund M., Lycke M., Broberg J., Lundberg M., Assarsson E., Olovsson M., Stålberg K., Sundfeldt K., Gyllensten U. High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer. Communications Biology, 2019, vol. 2, art. 221. https://doi.org/10.1038/s42003-019-0464-9

3. Kwon Y. W., Jo H. S., Bae S., Seo Y., Song P., Song M., Yoon J. H. Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery. Frontiers in Medicine, 2021, vol. 8, pp. 747–760. https://doi.org/10.3389/fmed.2021.747333

4. Gheybi E., Hosseinzadeh P., Tayebi-Khorrami V., Rostami M., Soukhtanloo M. Proteomics in decoding cancer: A review. Clinica Chimica Acta, 2025, vol. 574, art. 120132. https://doi.org/10.1016/j.cca.2025.120302

5. Nisa K. U., Tarfeen N., Wani S., Nisa Q., Ali Sh., Wali A. F. Proteomic approaches in the study of cancers. Proteomics. A Promising Approach for Cancer Research. San Diego, 2023, сh. 8, pp. 205–217. https://doi.org/10.1016/b978-0-323-950725.00002-x

6. Lv D., Li D., Cai Y., Guo J., Chu S., Yu J., Liu K., Jiang T., Ding N., Jin X., Li Y., Xu J. CancerProteome: a resource to functionally decipher the proteome landscape in cancer. Nucleic Acids Research, 2024, vol. 52, no. D1. pp. D1155–D1162. https://doi.org/10.1093/nar/gkad824

7. Giurini E. F., Godla A., Gupta K. H. Redefining bioactive small molecules from microbial metabolites as revolutionary anticancer agents. Cancer Gene Therapy, 2024, vol. 31, no. 2, pp. 187–206. https://doi.org/10.1038/s41417-023-00715-x

8. Mohamed A. N., Mohamed A. K. S. H., Zahran A. M., Gad A. M., Mekky A. E. Antimicrobial, anti-inflammatory, anticancer and antiviral activity of bioactive compounds from Pseudomonas aeruginosa isolated from Mediterranean Sea, Alexandria, Egypt. Microbial Biosystems, 2025, vol. 10, no. 1, pp. 123–134. https://doi.org/10.21608/mb.2025.322359.1173

9. Shapira M. A., Verameyenka K. G., Liavonchyk K. V., Dobysh A. A., Yantsevich A. V., Maksimova N. P. Novel approach of phenazine derivatives isolation from Pseudomonas culture medium. Process Biochemistry, 2021, vol. 111, no. 2, pp. 325–331. https://doi.org/10.1016/j.procbio.2021.11.004

10. Zhyzneyskaya A. A., Lukashevich A. A., Maksimova N. P., Veremeenko E. G. The Cytotoxic Activity of Phenazine Compounds from Pseudomonas chlororaphis subsp. aurantiaca against the HeLa Cell Line. Molecular Genetics, Microbiology and Virology, 2023, vol. 38, no. 4, pp. 215–221. https://doi.org/10.3103/S0891416823040079

11. Gerster S., Kwon T., Ludwig C., Matondo M., Vogel C., Marcotte E. M., Aebersold R., Bühlmann P. Statistical Approach to Protein Quantification. Molecular and Cellular Proteomics, 2014, vol. 13, no. 2, pp. 666–677. https://doi.org/10.1074/mcp.m112.025445

12. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry, 1951, vol. 193, no. 1, pp. 265–275, https://doi.org/10.1016/s0021-9258(19)52451-6

13. Alqarni B., Colley B., Klebensberger J., McDougald D., Rice S. A. Expression stability of 13 housekeeping genes du ring carbon starvation of Pseudomonas aeruginosa. Journal of Microbiological Methods, 2016, vol. 127, pp. 182–187. https://doi.org/10.1016/j.mimet.2016.06.008

14. Guo J., Huang M., Deng S., Wang H., Wang Z., Yan B. Highly expressed RPLP2 inhibits ferroptosis to promote hepato cellular carcinoma progression and predicts poor prognosis. Cancer Cell International, 2023, vol. 23, no. 1, art. 278. https://doi.org/10.1186/s12935-023-03140-0

15. Yang Q., Meng X., Chen J., Li X., Huang Y., Xiao X., Li R., Wu X. RPLP2 activates TLR4 in an autocrine manner and promotes HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma. Cell Death Discovery, 2023, vol. 9, no. 1, art. 440. https://doi.org/10.1038/s41420-023-01719-0

16. Artero-Castro A., Castellvi J., García A., Hernández J., Ramón y Cajal S., LLeonart M. E. Expression of the ribosomal proteins Rplp0, Rplp1, and Rplp2 in gynecologic tumors. Human Pathology, 2011, vol. 42, no. 2, pp. 194–203. https:// doi.org/10.1016/j.humpath.2010.04.020

17. Zhang H., Liu J., Dang Q., Wang X., Chen J., Lin X., Yang N., Du J., Shi H., Liu Y., Han J. Ribosomal protein RPL5 regulates colon cancer cell proliferation and migration through MAPK/ERK signaling pathway. BMC Molecular and Cell Biology, 2022, vol. 23, no. 1, art. 48. https://doi.org/10.1186/s12860-022-00448-z

18. Su Q., Sun H., Mei L., Yan Y., Ji H., Chang L., Wang L. Ribosomal proteins in hepatocellular carcinoma: mysterious but promising. Cell and Bioscience, 2024, vol. 14, art. 133. https://doi.org/10.1186/s13578-024-01316-3

19. Liu Y., Lai S., He J., Wan J., Fu F., Jinlong Y. Targeting RPL23 restores chemosensitivity of cisplatin-resistant ovarian carcinoma by inhibiting EMT. Cytotechnology, 2022, vol. 74, no. 3, pp. 421–432. https://doi.org/10.1007/s10616-022-00535-1

20. Price-Whelan A., Dietrich L. E., Newman D. K. Rethinking ‘secondary’ metabolism: physiological roles for phenazine antibiotics. Nature Chemical Biology, 2006, vol. 2, pp. 71–78. https://doi.org/10.1038/nchembio764